With a historic WHO resolution adopted this week giving countries, for the first time, a mandate to address liver disease affecting 1.5 billion people worldwide, this momentum is strongly reflected at the ongoing European Association for the Study of the Liver 2026 congress in Barcelona. The mandate positions liver disease alongside cancer, cardiovascular disease and diabetes as a core global health priority. Read More
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that autoimmunity might underlie the persistent neurological symptoms seen in long COVID, researchers at Yale University and Mount Sinai now reinforce this hypothesis. SARS-CoV-2 infection appears to trigger an autoimmune mechanism that drives chronic pain, fatigue and cognitive impairment in some patients. Read More
Bleednfire Therapeutics has launched, having secured nondilutive funding from Innosuisse, Venture Kick, the Gebert Rüf Foundation Innobooster program and Kickfund. It is co-founded by Landmark Bioventures AG and leading KOLs from the University of Bern and Inselspital (Bern University Hospital). Read More
At the ongoing European Association for the Study of the Liver 2026 annual meeting in Barcelona, researchers from Oricell Therapeutics Co. Ltd. presented data on a CAR T-cell approach targeting glypican 3 (GPC3) – OriC-902 – for the treatment of GPC3+ hepatocellular carcinoma (HCC). Read More
Open Source Therapeutics Co. Ltd. has reported new nitrogen-containing heterocyclic compounds acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors potentially useful for the treatment of cancer. Read More
Reprogram Biosciences Inc., a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, has announced the close of its seed financing, bringing the total capital raised to $6 million since the company’s founding in 2025. Read More
Protuoso Biosciences has announced the close of an oversubscribed $9.5 million seed financing round, the proceeds of which will be used to advance its multifunctional protein engineering platform and broad pipeline across cardiometabolic, oncology and autoimmune diseases. Read More
Scinnohub Pharmaceutical Co. Ltd. has disclosed new biazacycloalkane compounds acting as menin (MEN1)/KMT2A (MLL) and/or MEN1 (M327I mutant)/KMT2A (MLL) and/or MEN1 (T349M mutant)/KMT2A (MLL) interaction inhibitors potentially useful for the treatment of cancer and diabetes. Read More
Amplia Therapeutics Ltd. has discovered new focal adhesion kinase (FAK) inhibitors potentially useful for the treatment of cancer and fibrosis. Read More
Traws Pharma Inc. has reported that it is advancing a novel proprietary broad-spectrum combination antiviral agent with potential utility against hantavirus, Ebola and Lassa. Read More
Hutchmed Ltd. has identified new antibody-drug conjugates (ADCs) comprising an antibody targeting EGFR (HER1; erbB1) linked to cytotoxic drug potentially useful for the treatment of cancer and autoimmune diseases. Read More
Zhongshan Laibo Ruichen Biomedicine Co. Ltd. has patented new polypeptides and their drug conjugates potentially useful for the treatment of osteoporosis. Read More
Conexeu Sciences Inc. has launched a preclinical development program for B.R.E.A.S.T. (Bio-Regenerative Ergonomically Architected Smart Tissue), its 3D-printed bioregenerative breast matrix, at the Wake Forest Institute for Regenerative Medicine (WFIRM), a leading regenerative medicine research organization.
